AIDS and Cancer Virus Program

Photo of Dr. Lifson

Jeffrey D. Lifson, M.D.

Director, AIDS and Cancer Virus Program
PI/Principal Investigator, Retroviral Pathogenesis Section

Leidos Biomedical Research, Inc.
Frederick National Laboratory for Cancer Research
Frederick, MD 21702-1201

Tel: 301-846-1408
Fax: 301-846-5588


Dr. Lifson received his M.D. from Northwestern University Medical School in 1982, then pursued residency and research fellowship training in the Department of Pathology at the Stanford University School of Medicine. He became involved in AIDS-related research in 1983, playing a key role in establishing the first program in the United States to try to prevent transfusion-mediated transmission of AIDS through laboratory testing, while also conducting basic in vitro studies of AIDS pathogenesis. After several years of continuing research in AIDS pathogenesis while working in the biotechnology industry, during which time he helped pioneer the development and application of quantitative molecular methods for monitoring HIV replication in infected individuals. Dr. Lifson moved to the Frederick National Laboratory for Cancer Research in 1995, establishing the Retroviral Pathogenesis Section within the AIDS Vaccine Program. His work there has focused on the continuing development and application of quantitative virological and immunological methods for understanding retroviral pathogenesis and evaluating approaches for the prevention and treatment of retroviral infection and AIDS. In 2002, Dr. Lifson was named the director of the AIDS Vaccine Program, which became the AIDS and Cancer Virus Program in 2008.

Research Description

The Retroviral Pathogenesis Section conducts both in vitro and in vivo studies aimed at improving our understanding of the basis of lentiviral pathogenesis, particularly those aspects relevant to the development and evaluation of effective means of preventing and treating HIV infection and AIDS. The work spans a broad scope from in vitro studies of the structure of viral molecules involved in infection, to the interaction of viral particles with immune system cells, to in vitro studies, to in vivo studies in non-human primate models. The work emphasizes both applied studies such as the in vitro and in vivo evaluation of candidate vaccine and treatment approaches (immunogens, adjuvants, modes of immunization) and more basic studies aimed at characterizing fundamental processes of virus/host interactions potentially relevant to prevention and treatment. Areas of particular interest include development of improved non-human primate models involving minimally chimeric HIV strains, non-human primate models for evaluating virus suppressive antiretroviral drug treatment and approaches for targeting residual virus and latently infected reservoirs in treated individuals, the dynamics of virus/host interactions during primary infection, the mechanistic basis and consequences of chronic generalized immune activation in pathogenic primate lentiviral infection, and characterization of the virus/host interactions associated with situations of effective host control of replication, including vaccine induced protection.

Key Collaborators

  • Cristian Apetrei, University of Pittsburgh
  • Nina Bhardwaj, New York University
  • Paul Bieniasz, HHMI/Rockefeller University/ADARC
  • Jason Brenchley, NIAID/NIH
  • Mary Carrington, NCI Frederick
  • Ron Desrosiers, University of Miami
  • Danny Douek, VRC/NIAID/NIH
  • David Evans, University of Wisconsin, WNPRC
  • Romas Geleziunas, Gilead Sciences
  • Ashley Haase, University of Minnesota
  • Beatrice Hahn, University of Pennsylvania
  • Theodora Hatziioannou, ADARC
  • Daria Hazuda, Merck Research Laboratories
  • Vanessa Hirsch, NIAID/NIH
  • Jim Hoxie, University of Pennsylvania
  • R. Paul Johnson, Emory University, YNPRC
  • Vineet KewalRamani, HIV-DRP/NCI
  • Mal Martin, NIAID/NIH
  • Louis Picker, OHSU/VGTI/ONPRC
  • Melissa Robbiani, The Population Council
  • Tim Schacker, University of Minnesota
  • Bob Seder, VRC/NIAID/NIH
  • George Shaw, University of Pennsylvania
  • Guido Silvestri, Emory University
  • Sriram Subramaniam, NCI
  • Ron Veazey, Tulane University/TNPRC

Recent Publications

  1. Del Prete GQ, Ailers B, Moldt B, Keele BF, Estes JD, Rodriguez A, Sampias M, Oswald K, Fast R, Trubey CM, Chertova E, Smedley J, LaBranche CC, Montefiori DC, Burton DR, Shaw GM, Markowitz M, Piatak M Jr, KewalRamani VN, Bieniasz PD, Lifson JD, Hatziioannou T: Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe 16(3):412-418, 2014. doi: 10.1016/j.chom.2014.08.003. PMID: 25211081
  2. Del Prete GQ, Shoemaker R, Oswald K, Lara A, Trubey CM, Fast R, Schneider DK, Kiser R, Coalter V, Wiles A, Wiles R, Freemire B, Keele BF, Estes JD, Quiñones OA, Smedley J, Macallister R, Sanchez RI, Wai JS, Tan CM, Alvord WG, Hazuda DJ, Piatak M Jr, Lifson JD: Effect of SAHA administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob Agents Chemother. 2014 Sep 2. pii: AAC.03746-14. [Epub ahead of print] PMID: 25182644
  3. Li Q, Zeng Z, Duan L, Voss JE, Smith AJ, Pambuccian S, Shang L, Wietgrefe S, Southern PJ, Reilly CS, Skinner PJ, Zupancic ML, Carlis JV, Piatak M Jr, Waterman D, Reeves RK, Masek-Hammerman K, Derdeyn CA, Alpert MD, Evans DT, Kohler H, Muller S, Robinson J, Lifson JD, Burton DR, Johnson RP, Haase AT: Live SIV vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol 193(6):3113-25, 2014. doi: 10.4049/jimmunol.1400820. Epub 2014 Aug 18. PMID: 25135832
  4. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, Del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren Jr RB, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC: Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511(7511):601-605, 2014. Epub 2014 Jul 9. PMID: 25043006
  5. Ling B, Piatak M Jr, Rogers L, Johnson A-M, Russel-Lodrigue K, Hazuda D, Lifson JD, Veazey RS: Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques. PLoS One 9(7):e102795, 2014. doi: 10.1371/journal.pone.0102795. eCollection 2014. PMID: 25033210
  6. Do T, Murphy G, Earl LA, Del Prete GQ, Grandinetti G, Estes JD, Rao P, Trubey CM, Thomas J, Li G, Spector J, Bliss D, Nath A, Lifson JD, Subramaniam S: Three-dimensional imaging of HIV-1 virological synapses reveals membrane architectures involved in virus transmission. J Virol 88(18):10327-10339, 2014. doi: 10.1128/JVI.00788-14. Epub 2014 Jun 25. PMID: 24965444
  7. Hatziioannou T, Del Prete GQ, Keele BF, Estes JD, McNatt MW, Bitzegeio J, Raymond A, Rodriguez A, Schmidt F, Mac Trubey C, Smedley J, Piatak M Jr, KewalRamani VN, Lifson JD, Bieniasz PD: HIV-1 induced AIDS in monkeys. Science 344(6190):1401-1405, 2014. doi: 10.1126/science.1250761. PMID: 24948736
  8. Del Prete GQ, Park H, Fennessey CM, Reid C, Lipkey L, Lewman L, Oswald K, Kahl C, Piatak M Jr, Quinones OA, Alvord WG, Smedley J, Estes JD, Lifson JD, Picker LJ, Keele BF: Molecularly tagged SIVmac239 synthetic swarm for tracking independent infection events. J Virol 88(14):8077-8090, 2014. doi: 10.1128/JVI.01026-14. Epub 2014 May 7. PMID: 24807714
  9. Martins MA, Wilson NA, Piaskowski SM, Weisgrau KL, Furlott JR, Bonaldo MC, Veloso de Santana MG, Rudersdorf RA, Rakasz EG, Keating KD, Chiuchiolo MJ, Piatak M Jr, Allison DB, Parks CL, Galler R, Lifson JD, Watkins DI: Vaccination with gene fragments of gag, vif, and nef affords partial control of viral replication after mucosal challenge with SIVmac239. J Virol 88(13):7493-7516, 2014. Epub 2014 Apr 16. PMID: 24741098
  10. Kizima L, Rodriguez A, Kenney J, Debry N, Mizenina O, Menon R, Seidor S, Zhang S, Levendosky K, Jean-Pierre N, Pugach P, Billegas G, Ford B, Gettie A, Blanchard J, Piatak M Jr, Lifson J, Paglini G, Teleshova N, Zydowsky T, Robbiani M, Fernandez-Romero J: A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS ONE 9(4):e94547, 2014. doi: 10.1371/journal.pone.0094547. eCollection 2014. PMID: 24740100
  11. Smedley J, Turkbey IB, Bernardo ML, Del Prete GQ, Estes JD, Griffiths GL, Kobayashi H, Choyke PL, Lifson JD, Keele BF: Tracking the luminal exposure and lymphatic drainage pathways of intravaginal and intrarectal inocula used in nonhuman primate models of HIV transmission. PLoS One 9(3):e92830, 2014. doi: 10.1371/journal.pone.0092830. eCollection 2014. PMID: 24667371
  12. Jalah R, Kulkarni V, Patel V, Rosati M, Alicea C, Bear J, Yu L, Guan Y, Shen X, Tomaras GD, Labranche C, Montefiori DC, Prattipati R, Pinter A, Bess J Jr, Lifson JD, Reed SG, Sardesai NY, Venzon DJ, Valentin A, Pavlakis GN, Felber BK: DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. PLoS One 9(3):e91550, 2014. doi: 10.1371/journal.pone.0091550. eCollection 2014. PMID: 24626482
  13. Hsu M, Keele BF, Aravantinou M, Krawczyk N, Seidor S, Abraham CJ, Zhang S, Rodriguez A, Kizima L, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernandez-Romero JA, Zydowsky TM, Robbiani M: Exposure to MIV-150 from a high-dose intravaginal ring results in limited selection of drug resistance mutations in SHIV-RT infected rhesus macaques. PLoS One 9(2):e89300, 2014. doi: 10.1371/journal.pone.0089300. eCollection 2014. PMID: 24586674
  14. Westmoreland S, Converse AP, Hrecka K, Hurley M, Knight H, Piatak M, Lifson J, Mansfield KG, Skowronski J, Desrosiers RC: SIV Vpx is essential for macrophage infection but not for development of AIDS. PLoS One 9(1):e84463, 2014. doi: 10.1371/journal.pone.0084463. eCollection 2014 Jan 21. PMID: 24465411
  15. Kline C, Ndjomou J, Franks T, Kiser R, Coalter V, Smedley J, Piatak M, Mellors J, Lifson J, Ambrose Z: Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One 8(12):e84275, 2013. doi: 10.1371/journal.pone.0084275. eCollection 2013. PMID: 24367650
  16. Sasikala-Appukuttan AK, Kim HO, Kinzel NJ, Hong JJ, Smith AJ, Wagstaff R, Reilly C, Piatak M Jr, Lifson JD, Reeves RK, Johnson RP, Haase AT, Skinner PJ: Location and dynamics of the immunodominant CD8 T cell response to SIV nef immunization and SIVmac251 vaginal challenge. PLoS One 8(12):e81623, 2013. doi: 10.1371/journal.pone.0081623. eCollection 2013. PMID: 24349100
  17. Hsu M, Aravantinou M, Menon R, Seidor S, Goldman D, Kenney J, Derby N, Gettie A, Blanchard J, Piatak M, Lifson J, Fernandez-Romero JA, Zydowsky T, Robbiani M: A combination microbicide gel protects macaques against vaginal SHIV-RT infection, but only partially reduces HSV-2 infection after a single high-dose co-challenge. AIDS Res Hum Retroviruses 30(2):174-183, 2014. doi: 10.1089/AID.2013.0165. Epub 2013 Nov 22. PMID: 24117013
  18. Rahmberg AR, Neidermyer WJ Jr, Breed MW, Alvarez X, Midkiff CC, Piatak M Jr, Lifson JD, Evans DT: Tetherin upregulation in SIV-infected macaques. J Virol 87(24):13917-13921, doi: 10.1128/JVI.01757-13. Epub 2013 Oct 9. PMID: 24109219
  19. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Fruh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ: Immune clearance of highly pathogenic SIV infection. Nature 502(7469):100-104, 2013. DOI: 10.1038/nature12519. PMID: 24025770. Published: 2013-09-01
  20. Earl LA, Lifson JD, Subramaniam S: Catching HIV 'in the act' with 3D electron microscopy. Trends Microbiol 21(8):397-404, 2013. DOI: 10.1016/j.tim.2013.06.004. PMID: 23850373.
  21. Martinelli E, Veglia F, Goode D, Guerra-Perez N, Aravantinou M, Arthos J, Piatak M Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M: The frequency of α4β7high memory CD4+ T cells correlates with susceptibility to rectal SIV infection. J Acquir Immune Defic Syndr 64(4):325-331, 2013. DOI: 10.1097/QAI.0b013e31829f6e1a. PMID: 23797688.
  22. Kenney J, Rodríguez A, Kizima L, Seidor S, Menon R, Jean-Pierre N, Pugach P, Levendosky K, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini MG, Zydowsky TM, Robbiani M, Fernández Romero JA: A potential non-ARV microbicide -- A modified zinc acetate gel is safe and effective against SHIV-RT and HSV-2 infection In vivo. Antimicrob Agents Chemother 57(8): 4001-4009, 2013. DOI: 10.1128/AAC.00796-13. PMID: 23752515.
  23. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, Gilbride RM, Lewis MS, Gilliam AN, Ventura AB, Malouli D, Xu G, Richards R, Whizin N, Reed JS, Hammond KB, Fischer M, Turner JM, Legasse AW, Axthelm MK, Edlefsen PT, Nelson JA, Lifson JD, Früh K, Picker LJ: Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340(6135):1237874, 2013. doi: 10.1126/science.1237874. PMID: 23704576
  24. Del Prete GQ, Lifson JD: Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies. Curr Opin HIV AIDS 8(4):262-272, 2013. doi:10.1097/COH.0b013e328361cf40. Epub 2013 May 21. PMID: 23698559
  25. Tjomsland V, Ellegård R, Kjölhede P, Wodlin NB, Hinkula J, Lifson JD, Larsson M: Blocking of integrins inhibits HIV-1 infection of human cervical mucosa immune cells with free and complement-opsonized virions. Eur J Immunol 43(9):2361-2372, 2013. doi: 10.1002/eji.201243257. Epub 2013 Jun 25. PMID: 23686382
  26. Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD, Beach RK, Lifson JD, Felber BK, Pavlakis GN: Characterization and favorable in vivo properties of heterodimeric soluble IL-15/IL-15Ra cytokine compared to IL-15 monomer. J Biol Chem 288(25):18093-18103, 2013. doi: 10.1074/jbc.M113.461756. Epub 2013 May 6. PMID:23649624
  27. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, Yuki Y, Del Prete GQ, Goulder P, Brumme ZL, Brumme CJ, John M, Mallal S, Nelson G, Bosch R, Heckerman D, Stein JL, Soderberg KA, Moody MA, Denny TN, Zeng X, Fang J, Moffett A, Lifson JD, Goedert JJ, Buchbinder S, Kirk GD, Fellay J, McLaren P, Deeks SG, Pereyra F, Walker B, Michael NL, Weintrob A, Wolinsky S, Liao W, Carrington M: Influence of HLA-C Expression level on HIV Control. Science 340(6128):87-91, 2013. doi: 10.1126/science.1232685.
  28. Tjomsland V, Ellegård R, Burgener A, Mogk K, Che KF, Westmacott G, Hinkula J, Lifson JD, Larsson M: Complement opsonization of HIV-1 results in a different intracellular processing pattern and enhanced MHC class I presentation by dendritic cells. Eur J Immunol 43(6):1470-1483, 2013. doi: 10.1002/eji.201242935. Epub 2013 Apr 24. PMID: 23526630
  29. Park H, Adamson L, Ha T, Mullen K, Hagen SI, Nogueron A, Sylwester AW, Axthelm MK, Legasse A, Piatak M Jr, Lifson JD, McElrath JM, Picker LJ, Seder RA: Polyinosinic-Polycytidylic acid is the most effective TLR adjuvant for SIV gag protein-induced T cell responses in nonhuman primates. J Immunol 190(8):4103-4115, 2013. doi: 10.4049/jimmunol.1202958. Epub 2013 Mar 15. PMID: 23509365
  30. Mendoza D, Migueles SA, Rood JE, Peterson B, Johnson S, Doria-Rose N, Schneider D, Rakasz E, Trivett MT, Trubey CM, Coalter V, Hallahan CW, Watkins D, Franchini G, Lifson JD, Connors M: Cytotoxic capacity of SIV-specific CD8(+) T cells against primary autologous targets correlates with immune control in SIV-infected rhesus macaques. PLoS Pathog 9(2):e1003195, 2013. doi: 10.1371/journal.ppat.1003195. Epub 2013 Feb 28. PMID: 23468632
  31. Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M Jr, Chertova E, Giavedoni LD, O’Connor DH, Lifson JD, Keele BK: Comparative characterization of transfection- and infection –derived SIV challenge stocks for in vivo non-human primate studies. J Virol 87(8):4584-4595, 2013, doi: 10.1128/JVI.03507-12. Epub 2013 Feb 13. PMID: 23408608
  32. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, von Gegerfelt A, Huang W, Guan Y, Keele BF, Bess JW Jr, Piatak M Jr, Lifson JD, Williams WT, Shen X, Tomaras GD, Amara RR, Robinson HL, Johnson W, Broderick KE, Sardesai NY, Venzon DJ, Hirsch VM, Felber BK, Pavlakis GN: DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. PNAS 110(8):2975-2980, 2013. doi: 10.1073/pnas.1215393110. Epub 2013 Jan 28. PMID: 23359688
  33. Vaccari M, Keele BF, Bosinger SE, Doster M, Ma ZM, Pollara J, Hryniewicz A, Ferrari G, Guan YJ, Forthal D, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller C, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G: Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 challenge exposure. J Virol 87(6):3538-3548, 2013. doi: 10.1128/JVI.02863-12. Epub 2013 Jan 16. PMID: 23325681
  34. Klatt NR, Canary LA, Sun X, Vinton CL, Funderburg NT, Morcock DR, Quiñones M, Deming CB, Perkins M, Hazuda DJ, Miller MD, Lederman MM, Segre JA, Lifson JD, Haddad EK, Estes JD, Brenchley JM: Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest 123(2):903-907, 2013. 2013 Jan 16. doi:pii: 66227. 10.1172/JCI66227. PMID: 23321668
  35. García F, Climent N, Guardo AC, Gil C, León A, Autran B, Lifson JD, Martínez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T: A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. DCV2/MANON07-ORVACS Study Group. Sci Transl Med 5(166):166ra2, 2013. doi: 10.1126/scitranslmed.3004682. PMID: 23283367
  36. Meyerson JR, Tran EE, Kuybeda O, Chen W, Dimitrov DS, Gorlani A, Verripps T, Lifson JD, Subramaniam S: Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci USA 110(2):513-518, 2013. doi: 10.1073/pnas.1214810110. Epub 2012 Dec 24. PMID: 23267106
  37. Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G: Antibodies with high avidity to the gp120 envelope protein in protection from SIVmac251 acquisition in an immunization regimen that mimics the RV-144 Thai Trial. J Virol 87(3):1708-1719, 2013. doi: 10.1128/JVI.02544-12. Epub 2012 Nov 21. PMID: 23175374
  38. Breed MW, Jordan AP, Aye PP, Lichtveld CF, Midkiff C, Schiro FR, Haggarty BS, Sugimoto C, Alvarez X, Sandler NG, Douek DC, Kuroda MJ, Pahar B, Piatak M Jr, Lifson JD, Keele BF, Hoxie JA, Lackner AA: Loss of a tyrosine-dependent trafficking motif in the SIV envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression. J Virol 87(3):1528-1543, 2013 doi: 10.1128/JVI.01928-12. Epub 2012 Nov 14. PMID: 23152518
  39. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA: Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503(7475):277-280, 2013. doi: 10.1038/nature12746. Epub 2013 Oct 30. PMID: 24172896
  40. Ling B, Rogers L, Johnson AM, Piatak M, Lifson J, Veazey RS: Effect of combination antiretroviral therapy on chinese Rhesus macaques of simian Immunodeficiency virus infection. AIDS Res Hum Retroviruses 29(11):1465-1474, 2013. DOI: 10.1089/AID.2012.0378. PMID: 23387294.
  41. Manrique J, Piatak M, Lauer W, Johnson W, Mansfield K, Lifson J, Desrosiers R: Influence of mismatch of env sequences on vaccine protection by live attenuated simian immunodeficiency virus. J Virol 87(13): 7246-7254, 2013. DOI: 10.1128/JVI.00798-13. PMID: 23637396. PMCID: PMC3700272.
  42. Tabb B, Morcock DR, Trubey CM, Quiñones OA, Hao XP, Smedley J, Macallister R, Piatak M Jr, Harris LD, Paiardini M, Silvestri G, Brenchley JM, Alvord WG, Lifson JD, Estes JD: Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 207(6):880-892, 2013 doi: 10.1093/infdis/jis643. Epub 2012 Oct 19. PMID: 23087435
  43. Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, Piaskowski SM, Duan L, Seese A, Gladden AD, Weisgrau KL, Furlott JR, Kim YI, Veloso de Santana MG, Rakasz E, Capuano S 3rd, Wilson NA, Bonaldo MC, Galler R, Allison DB, Piatak M Jr, Haase AT, Lifson JD, Allen TM, Watkins DI: Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 491(7422):129-133, 2012. doi: 10.1038/nature11443. Epub 2012 Sep 30. PMID: 23023123
  44. Brenchley JM, Vinton C, Tabb B, Hao XP, Connick E, Paiardini M, Lifson JD, Silvestri G, Estes JD: Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 120(20):4172-4181, 2012. doi: 10.1182/blood-2012-06-437608. Epub 2012 Sep 18. PMID: 22990012
  45. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Iii MD, Swanson T, Legasse AW, Sylwester A, Hansen SG, Smith AT, Stafova P, Shoemaker R, Li Y, Oswald K, Axthelm MK, McDermott A, Ferrari G, Montefiori DC, Edlefsen PT, Piatak M Jr, Lifson JD, Sékaly RP, Picker LJ: Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 18(11):1673-1681, 2012. doi: 10.1038/nm.2934. Epub 2012 Sep 9. PMID: 22961108
  46. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Robbiani M, Zydowsky TM: An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med 4(150):150ra123, 2012. PMID: 22956201
  47. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT: ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8(8):e1002890, doi: 10.1371/journal.ppat.1002890 2012. Epub 2012 Aug 23. PMID: 22927823
  48. Jasny E, Geer S, Frank I, Vagenas P, Aravantinou M, Salazar AM, Lifson JD, Piatak M Jr, Gettie A, Blanchard JL, Robbiani M: Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy. J Acquir Immune Defic Syndr 61(4):425-435, 2012. doi:10.1097/QAI.0b013e318266be53. PMID: 22820802
  49. Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, Abraham CJ, Menon R, Seidor S, Goldman D, Kenney J, Villegas G, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Teleshova N, Robbiani M: The nonnucleoside teverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against Simian/Human Immunodeficiency Virus-RT infection. AIDS Res Hum Retroviruses 28(11):1467-1475, 2012. doi: 10.1089/AID.2012.0080. Epub 2012 Aug 27. PMID: 22816564
  50. Kenney J, Singer R, Derby N, Aravantinou M, Abraham CJ, Menon R, Seidor S, Zhang S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M: A single dose of a MIV-150/zinc acetate gel provides 24 hours of protection against vaginal SHIV-RT infection, with more limited protection rectally 8-24 hours after gel use. AIDS Res Hum Retroviruses 28(11):1476-1484, 2012. doi: 10.1089/AID.2012.0087. Epub 2012 Jul 30. PMID: 22737981
  51. Lifson JD, Haigwood NL: Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Cold Spring Harb Perspect Med 2(6):a007310, 2012. PMID: 22675663
  52. Klatt NR, Estes JD, Sun X, Ortiz AM, Barber JS, Harris LD, Cervasi B, Yokomizo LK, Pan L, Vinton CL, Tabb B, Canary LA, Dang Q, Hirsch VM, Alter G, Belkaid Y, Lifson JD, Silvestri G, Milner JD, Paiardini M, Haddad EK, Brenchley JM: Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol 5(6):646-657, 2012. doi: 10.1038/mi.2012.38. Epub 2012 May 30. PMID: 22643849
  53. Budde M, Greene J, Chin E, Ericsen A, Scarlotta M, Cain B, Pham N, Becker E, Harris M, Weinfurter J, O’Connor S, Piatak M, Lifson J, Gostick E, Price D, Friedrich T, O’Connor D: Specific CD8+ T cell responses correlate with control of SIV replication in Mauritian cynomolgus macaques. J Virol 86(14):7596-7604, 2012. Epub 2012 May 9. PMID: 22573864
  54. Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI: A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 30(30):4465-4475, 2012. Epub 2012 May 6. PMID: 22569124
  55. Okoye AA, Rohankhedkar M, Abana C, Pattenn A, Reyes M, Pexton C, Lum R, Sylwester A, Planer SL, Legasse A, Park BS, Piatak M Jr, Lifson JD, Axthelm MK, Picker LJ: Naïve T cells are dispensable for memory CD4+ T cell homeostasis in progressive simian immunodeficiency virus infection. J Exp Med 209(4):641-651, 2012. Epub 2012 Mar 26. PMID: 22451717
  56. Kearney MF, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, Devere White RW, Del Prete GQ, Mellors JW, Lifson JD, Kewalramani VN, Pathak VK, Coffin JM, Le Grice SF: Nucleic acid, antibody, and virus culture methods to detect xenotropic MLV-related virus in human blood samples. Adv Virol 2011:272193, 2011. Epub 2011 Nov 17. PMID: 22312339
  57. Del Prete GQ, Kearney MF, Spindler J, Wiegand A, Chertova E, Roser JD, Estes JD, Hao XP, Trubey CM, Lara A, Lee K, Chaipan C, Bess JW Jr, Nagashima K, Keele BF, Pung R, Smedley J, Pathak VK, Kewalramani VN, Coffin JM, Lifson JD: Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques. J Virol 86(6):3152-3166, 2012. Epub 2012 Jan 11. PMID: 22238316
  58. Picker LJ, Hansen SG, Lifson JD: New paradigms for HIV/AIDS vaccine development. Annu Rev Med 63:95-111, 2012. Epub 2011 Sep 19. PMID: 21942424


  • Gregory Q. Del Prete, Ph.D., Staff Scientist
  • Robert J. Gorelick, Ph.D., Staff Scientist
  • Douglas K. Schneider, Research Associate II